Research Synthesis: Aerobic exercise

We therefore conducted an AI-assisted structured evidence synthesis with a per-source audit trail, restricting inclusion to studies with reported p-values, effect directions, and design metadata, and pre-specifying outcome classes (cardiometabolic, muscle function, bone, immune, and contextual) so that disagreements across the curated set could be mapped transparently rather than smoothed away.

The evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 20 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 148 cross-study disagreements across the evidence base.

Positive study-level signals are not the dominant direction in any outcome class; null signals are summarized in the contextual adjacent evidence, cardiometabolic, dosing and pharmacokinetics, and skeletal, fracture, and bone outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the muscle function and immune outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that Aerobic exercise remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

Abstract

Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on Aerobic exercise across 31 included source papers and 1387 high-confidence extracted claims.

Positive study-level signals are summarized in the muscle function, contextual adjacent evidence and cardiometabolic outcome classes, null signals in the contextual adjacent evidence, cardiometabolic, skeletal, fracture, and bone outcome classes, and negative signals in the cardiometabolic outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

A stronger future corpus would be expected to add larger direct trials, cleaner endpoint harmonization, and repeated evidence in the same outcome class. Until then, confidence remains calibrated to the currently retained evidence profile.

This framing also preserves comparability across topics. The same rules can classify a biomedical intervention, a management field experiment, or an economics policy corpus by asking what evidence is direct, what evidence is indirect, and what mechanism connects the two.

Introduction

The human randomized evidence base for Aerobic exercise in the present synthesis is broad in scope and heterogeneous in design, which is both a strength and a complication. Translational relevance to humans remains uncertain. Endpoints are similarly diverse: cardiorespiratory fitness measured as peak oxygen uptake, body-fat percentage, inflammatory biomarkers such as C-reactive protein, cognitive and executive-function batteries, neuroimaging-derived connectivity indices, vascular measures including arterial stiffness, and behavioral outcomes such as drug craving. This heterogeneity is, in part, the point — the geroscience framing demands that multiple aging-relevant outcomes be assessed in parallel — but it also makes any simple summary of Aerobic exercise's effects across studies inherently fragile, and motivates the structured cross-outcome synthesis that this paper undertakes.

Within this evidence base, several unresolved questions stand out, and they cut across the mechanistic, clinical, and population dimensions of the Aerobic exercise case. The first concerns the translation problem: the field has collected a sizable mechanistic literature suggesting that Aerobic exercise engages hallmarks of aging — mitochondrial function, inflammation, vascular health, neuroplasticity — but the mapping from those mechanistic signals to hard clinical endpoints remains incomplete, and a general caution that surrogate associations do not guarantee hard-outcome validity (Ioannidis 2005) applies here as much as in any drug-development program. The second concerns tradeoffs and ceiling effects: typical attrition in long-duration trials of older adults can approach 20% (Schulz 2010), some cardiometabolic augmentation strategies appear to add hemodynamic and vascular benefit without further improving cardiorespiratory fitness, glucose, lipids, or inflammation (Steward 2025), and dose-response relationships between Aerobic exercise intensity, duration, and outcomes are not well characterized across the included studies. The third concerns the boundary conditions of the comparison condition: when Aerobic exercise is contrasted with no intervention, stretching and toning, or low-intensity hospital-based programs, effect sizes and significance patterns shift, raising real questions about how much of the observed benefit is Aerobic exercise-specific versus a generic effect of structured activity. These unresolved questions are not reasons to dismiss the Aerobic exercise case, but they are the reasons a careful synthesis is needed.

This paper takes a structured-evidence approach to making sense of the Aerobic exercise literature as it currently stands, with the explicit goal of distinguishing robust signals from artifacts of design heterogeneity. The contribution is organized around three analytical moves. First, we surface the cross-outcome tensions — 148 non-orthogonal pairwise disagreements, null-versus-positive contrasts, and agreements — that exist across the included study set, and we ask whether these tensions localize to specific outcome classes, populations, or intervention parameters rather than being uniformly distributed noise. Second, we apply structured evidence weighting that separates clinical and functional outcomes (e.g., cardiorespiratory fitness, muscle function, inflammatory biomarkers) from mechanistic and contextual outcomes (e.g., neuroimaging connectivity, executive-function battery scores, behavioral correlates), and we ask whether each tier independently supports a geroprotective interpretation of Aerobic exercise. Third, we attempt to separate the question of whether Aerobic exercise modifies measurable aging-relevant biology — for which the mechanistic case is reasonably strong — from the harder question of whether those modifications translate into durable, clinically meaningful anti-aging benefit in humans, for which the current RCT evidence remains incomplete. Throughout, we maintain the framing that Aerobic exercise is a candidate with genuine mechanistic plausibility and population-scale accessibility, but with a clinical evidence base that is not yet adequate to declare victory, and with boundary conditions — dose, population, comparator, duration — that have been insufficiently characterized. The remainder of the synthesis develops this argument outcome by outcome, makes explicit the tensions and agreements identified in the curated set, and concludes with the specific trials, populations, and design features that would be most informative for the next generation of Aerobic exercise anti-aging research.

Background

The geroscience agenda positions chronic disease prevention and healthspan extension as derivative problems of the biological hallmarks of aging, an organizing framework that has reshaped how candidate geroprotectors — including Aerobic exercise — are evaluated across the translational pipeline. Within that framework, Aerobic exercise is unusual in that it is simultaneously a behavior, a cardiorespiratory stimulus, and a multi-organ physiological perturbation, which complicates its regulatory classification but also explains the breadth of its hypothesized mechanism-of-action profile. Mechanistic claims therefore need to be tied to specific hallmarks (mitochondrial dysfunction, cellular senescence, inflammation, vascular aging) and to specific trial-level signals rather than to global promises of rejuvenation. The Aerobic exercise literature relevant to aging is correspondingly heterogeneous, spanning preclinical rodent work, mechanistic human biopsy studies, behavior-change trials, and pragmatic effectiveness evaluations in clinical populations. This background orients the reader to that landscape, sets up the integration thesis, and flags the methodological seams — endpoint heterogeneity, mechanism-to-clinic translation, treatment-duration uncertainty, and concurrent-intervention contamination — that the synthesis tables and cross-study disagreement map explore in detail.

Preclinical and disease-model data provide the principal mechanistic scaffolding for Aerobic exercise effects, and the curated evidence base touches on several of the canonical pathways invoked in geroscience. Tanaka 2012 added an 8-week intermittent, moderate-intensity protocol in healthy young subjects with reductions in arterial stiffness parameter β and pressure-strain elastic modulus E_p (P < 0.01 and P < 0.05 respectively), consistent with vascular-aging modification. The source set does not, however, support a fully specified causal chain from Aerobic exercise dose to hallmark reversal, and the mechanistic narratives can be interpreted as plausibility scaffolding rather than confirmed pathway maps.

The trial-level landscape sampled here is dominated by small-to-moderate RCTs and meta-analytic syntheses rather than by the kind of large, hard-outcome pivotal trials that the broader field is often criticized for lacking. Translational relevance to humans remains uncertain. The most distinctive negative signal in the source set comes from Steward 2025, where post-exercise hot water immersion did not further improve cardiorespiratory fitness, glucose, lipids, or inflammation, illustrating how additive interventions can produce null-to-negative directionality on the very outcomes that Aerobic exercise alone is hypothesized to move. Long-duration trials powered for hard clinical endpoints — falls, hospitalization, mortality — are essentially absent from the source set, and this shapes how the synthesis must be interpreted.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-aerobic_exercise-v06-DAILY-2026-06-12T08-02-51Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-12.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• aerobic exercise AND aging AND randomized trial
• endurance training AND older adults AND cognition
• walking program AND elderly AND frailty
• cardiorespiratory fitness AND mortality AND cohort
• aerobic exercise AND VO2max AND older adults

Eligibility criteria

• Sources whose primary content addresses aerobic exercise.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 757 records in the receipt-candidate union, 195 were classified as source candidates and 31 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	757
Classified source candidates	195
No extractable claims	131
None-only claim binding	66
Mixed partial-or-none claim-binding candidates	226
Partial-only claim-binding candidates	99
Strict high-confidence sources	40
Admitted final sources	31

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, immune, muscle function, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=17; claims=805	no extracted directional signal in 9/17 sources	13 indirect; 4 review	limited corpus depth in this outcome class
Muscle Function	n=7; claims=146	positive signal in 3/7 sources	2 indirect; 5 review	limited corpus depth in this outcome class
Cardiometabolic	n=4; claims=338	no extracted directional signal in 2/4 sources	3 indirect; 1 review	limited corpus depth in this outcome class
Dosing and Pharmacokinetics	n=1; claims=13	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Immune	n=1; claims=18	mixed signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Skeletal, Fracture, and Bone	n=1; claims=67	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

Results Summary

• Contextual Adjacent Evidence: n=17; claims=805; no extracted directional signal in 9/17 sources | directness: 13 indirect; 4 review; main limitation: no direct clinical anchor.
• Muscle Function: n=7; claims=146; benefit signal in 3/7 sources | directness: 2 indirect; 5 review; main limitation: no direct clinical anchor.
• Cardiometabolic: n=4; claims=338; no extracted directional signal in 2/4 sources | directness: 3 indirect; 1 review; main limitation: no direct clinical anchor.
• Dosing and Pharmacokinetics: n=1; claims=13; no extracted directional signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.
• Immune: n=1; claims=18; mixed signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor.
• Skeletal, Fracture, and Bone: n=1; claims=67; no extracted directional signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.

Cardiometabolic Outcomes

Four studies in the curated corpus directly addressed cardiometabolic endpoints of aerobic exercise, spanning middle-aged inactive adults, obese older seniors, sedentary adults in a network meta-analysis, and healthy active seniors in a crossover reliability study.

Quantitative findings diverge sharply across these four sources. Per-study endpoint p-values are catalogued in the supplementary evidence tables.

Mechanistically, the cardiometabolic pattern is best read as a stratification by population and co-intervention rather than a single physiological pathway. The clinical RCT substrate from Elsayed 2023 extends the same aerobic-exposure logic into an obese-senior, hypercoagulability-resistant population, where the strongest contrasts (P < 0.001) implicate haemostasis rebalancing as the dominant cardiometabolic mechanism.

The within-corpus tensions on cardiometabolic endpoints are pronounced and warrant explicit discussion. Huang 2025's null direction conflicts with Elsayed 2023's positive direction (severity 3), and Huang 2025 also conflicts with Steward 2025's negative direction (severity 3). Donath 2017's null reliability framing agrees with Huang 2025's null aggregate framing (severity 1) but disagrees with Elsayed 2023's positive direction (severity 3) and with Steward 2025's negative direction (severity 3). These six cross-study disagreements, summarized in the Cross-Domain Synthesis, indicate that the cardiometabolic case for aerobic exercise as currently constituted is incomplete: positive signals in obese-senior RCTs coexist with null or negative signals in middle-aged and sedentary populations, and the boundary conditions — co-intervention type, population adiposity, and acute versus chronic exposure — remain to be established.

Contextual Adjacent Evidence Outcomes

Clinical RCT and meta-analytic evidence clusters around cardiorespiratory fitness (CRF) as the principal endpoint. Elnaggar 2026, in pediatric leukemia survivors, showed graded aerobic exercise produced superior cardiorespiratory and functional outcomes versus constant-load and control conditions, with multiple comparisons at P < 0.001.

Immune Outcomes

The principal evidence base for immune outcomes in the corpus is anchored by a systematic review with meta-analysis of randomized controlled trials examining the effect of aerobic exercise on inflammatory markers in healthy middle-aged and older adults (Zheng 2019). The synthesis aggregated trials of aerobic training interventions in this population and quantified pooled effects on canonical inflammation biomarkers, including C-reactive protein (CRP) and additional cytokines measured across the included studies. The meta-analytic framework permits attribution of effect direction and statistical significance at the pooled rather than per-study level, which is the unit relevant to this synthesis.

Quantitatively, the pooled analyses yielded effect-direction calls of mixed across the inflammatory endpoints examined, indicating that the direction of change was not uniform across markers (Zheng 2019). The reported p-values from the pooled comparisons — P = 0.0002, P = 0.0007 (appearing twice in the source), P = 0.0002, P = 0.0007, and P = 0.003 — establish that several of these pooled comparisons reached conventional statistical significance, while the overall effect direction is recorded as mixed, consistent with the possibility that some markers moved favorably, others less so, or that the pooled estimate was attenuated by inter-study heterogeneity. Per-study p-values and confidence intervals are catalogued in the supplementary evidence tables rather than restated here.

Mechanistically, the inflammatory-marker findings are coherent with the broader corpus pathways linking aerobic exercise to immune modulation through reductions in systemic low-grade inflammation, a substrate implicated in age-related functional decline (Zheng 2019). Because Zheng 2019 is a meta-analysis of human RCTs, the evidence it contributes sits at the clinical RCT tier of the mechanistic spectrum; the human RCT tier is the highest level of causal inference represented in the immune outcome class within the corpus. The review-graded directness label reflects that this is a synthesis of primary trials rather than a single mechanistic study, and the canonical trial id field is recorded as none because no individual trial identifier was extracted from the source.

The within-corpus tension for the immune outcome class is constrained by the fact that the cross-study disagreement map contained no same-outcome non-orthogonal pairs, so no inter-source disagreement is surfaced for this outcome in the present synthesis. Consequently, the immune subsection is single-source by design, and any apparent heterogeneity is internal to Zheng 2019's mixed effect direction call rather than a disagreement between independent corpus sources. This nullity in the cross-study disagreement map should not be over-interpreted as substantive consensus; it reflects the structural shape of the curated corpus for this outcome rather than independent replication. The reader is referred to the Cross-Domain Synthesis for tensions that span outcome classes, including the broader profile in which positive immune signals sit alongside null or mixed findings elsewhere.

Muscle Function Outcomes

The muscle function outcome class dominates the curated Aerobic exercise evidence base and spans clinical RCTs, observational cohorts, and narrative or systematic reviews. Lo 2021 randomized middle-aged and older adults with multimorbidity to individualized aerobic exercise training and reported physical activity and health-related physical fitness endpoints with multiple source-traced significance values (P = 0.011, P = 0.007, P = 0.019, P = 0.027, P = 0.043, P = 0.001). Baker 2010 conducted a six-month aerobic exercise trial in older adults with glucose intolerance, a recognized Alzheimer's disease risk factor, and reported improvements in executive function (MANCOVA, P = 0.04), cardiorespiratory fitness (MANOVA, P = 0.03), and insulin sensitivity (P = 0.05).

Quantitative findings cluster in two strata. The first stratum comprises direct clinical RCT evidence in older adults: Lo 2021's six-trend significance profile in middle-aged and older adults with multimorbidity and Baker 2010's three-endpoint positive signature (P = 0.04, P = 0.03, P = 0.05) anchor the positive end of the muscle function distribution. The second stratum is mixed or indirect: Hinchman 2022 reported an exercise-engagement-driven effect with mixed directionality, and Li 2025 — an observational cohort in adults — reported cascading effects on drug cravings mediated by cardiorespiratory fitness and inhibitory control at source-traced thresholds (P < 0.05, P < 0.05, P < 0.05, P < 0.01, P < 0.01, P < 0.01). Weber 2024, a scoping review of female cognition, contributed additional mixed-direction evidence (P < 0.01, P = 0.016, P < 0.05, P < 0.001, P = 0.003, P = 0.048) by examining pregnancy and menstrual cycle periodicity as moderators of the aerobic–cognition relationship.

Mechanistically, the muscle function outcomes are not isolated strength or hypertrophy endpoints but functional readouts that are coupled to cardiorespiratory adaptation. Preclinical and mechanistic human studies summarized across the corpus link VO2max-style adaptation to executive control, insulin sensitivity, and inhibitory processing — the same substrate Baker 2010 quantified at P = 0.05 for insulin sensitivity and at P = 0.04 for executive function. Lo 2021's source-traced six-value significance profile (P = 0.011 through P = 0.001) extends this mechanistic chain into a multimorbid older-adult population, supporting the inference that cardiorespiratory gain is the proximal mediator of the cognitive and functional gains observed across these trials.

Within-corpus tensions are most visible in the muscle function class. Baker 2010 (positive) and Li 2025 (positive) agree at severity 1, and both align with Lo 2021 (positive), producing a convergent positive cluster for direct RCT evidence in older adults and incarcerated adults respectively. The most consequential tension is between Baker 2010 (positive, P = 0.04 executive function) and Weber 2024 (mixed, P = 0.016 to P = 0.048), which is best read as a population-and-moderator disagreement: Baker 2010 enrolled glucose-intolerant older adults, whereas Weber 2024 highlighted female-specific moderators such as menstrual cycle periodicity that may attenuate the positive signal. Together these within-corpus tensions argue that the Aerobic exercise anti-aging case is mechanistically plausible but boundary-condition-dependent.

Skeletal, Fracture, and Bone Outcomes

Within the curated aerobic-exercise evidence base, only one source, Egan 2013, maps to the skeletal-fracture outcome class, and it is classified as indirect with respect to fracture endpoints. The study enrolled eight healthy, sedentary males who cycled for 60 minutes at 80% of peak oxygen consumption (VO2peak) per day for fourteen consecutive days, with transcriptomic and proteomic kinetics as the principal readouts. Fracture incidence was not a prespecified endpoint, and the source does not report any fracture event, bone mineral density change, or hazard ratio for fracture. Accordingly, the evidence is mechanistic rather than clinical, and any inference about skeletal-fracture risk reduction from aerobic training must be drawn through the lens of the gene-expression and protein-adaptation data rather than from a direct outcome count.

The source's effect direction is null for the skeletal-fracture outcome class, which is consistent with the absence of any direct fracture endpoint. No hazard ratio, odds ratio, or relative risk for fracture is reported, and no sample-size calculation relevant to bone outcomes is provided. The numerics therefore describe molecular adaptation kinetics, not clinical skeletal events, and the reader is referred to the supplementary evidence tables for the per-study endpoint mapping.

Mechanistically, the Egan 2013 transcript and protein kinetics provide a plausible biological substrate by which habitual aerobic exercise could influence skeletal integrity, even though the study itself does not measure bone. The cited gene- and protein-level adaptations imply coordinated remodeling of the muscle envelope that loads bone during weight-bearing cycling, a pathway that, in the broader literature, is invoked to explain the indirect skeletal benefits of aerobic training. Because the source is classified as mechanistic human data rather than a clinical RCT of fracture outcomes, the finding can be interpreted as a hypothesis-generating signal for skeletal adaptation rather than as evidence of fracture-risk modification. The within-corpus cross-study disagreement map lists no non-orthogonal same-outcome pairs for this class, indicating no internal disagreement on the indirectness or direction of the available evidence.

The principal within-corpus tension for the skeletal-fracture class is not between competing human trials but between the mechanistic optimism of Egan 2013 and the absence of any direct fracture trial in the curated set. Egan 2013's null effect direction on this outcome class reflects the lack of a clinical fracture endpoint, not a failed trial, and this framing distinguishes a true negative from a missing measurement. For the synthesis to advance from mechanistic plausibility to clinical claim, a future source would need to contribute a clinical RCT or prospective cohort with adjudicated fracture events and a reported hazard ratio or relative risk. In the present corpus, the skeletal-fracture case for aerobic exercise rests on a single indirect mechanistic study, and the boundary conditions — including sex, age, and baseline bone status — remain entirely to be established.

Dosing and Pharmacokinetics Outcomes

Within-corpus tensions are most visible in cognitive and brain-endpoint RCTs. The study indexed training dose against cardiorespiratory fitness (CRF) change and tested whether resting plasma neurotrophic factors — a candidate mechanistic substrate in Alzheimer’s dementia — tracked that exposure. The endpoint architecture is correlational rather than interventional, and the analytic plan computed three correlations per CRF-biomarker combination, with significance evaluated at each (Salisbury 2023).

The direction of effect in the source is recorded as null, consistent with the three p-values clustering well above 0.05. The source does not report an effect size estimate, hazard ratio, or odds ratio for any of the three comparisons, so the quantitative footprint of this trial within the synthesis is restricted to the three p-values and the absence of an effect-direction signal (Salisbury 2023).

Mechanistically, the design implicitly treats plasma neurotrophic factors as dose-responsive biomarkers linking aerobic training dose to a downstream neurodegenerative endpoint, but the correlational layer between CRF change and biomarker change did not register a signal. Because the outcome class is tagged indirect, the relevance of Salisbury 2023 to a clinical pharmacokinetic question is mediated: it speaks to whether a training-dose surrogate (CRF change) reproduces a candidate biological signature, not to drug-like exposure–response. The mechanistic substrate therefore remains plausible but is not supported by the in-corpus human correlational evidence (Salisbury 2023).

No within-corpus tension pairs were registered for the dosing pharmacokinetics outcome class, so no comparator source exists to contest the Salisbury 2023 profile. The integrating brief nevertheless notes that null findings dominate the broader cardiometabolic and contextual other outcome classes across the 31 curated papers, and the present subsection is congruent with that pattern: a single observational cohort with a fully null correlational read-out. The boundary condition that would move this from null to informative — a longitudinal interventional design with a pre-specified CRF dose and a sensitive neurotrophic endpoint — is not satisfied by the current source set (Salisbury 2023).

Dosing and Pharmacokinetics remains a separate Results slice (n=1; claims=13; no extracted directional signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes.

Cross-Domain Synthesis

The most consequential tension in the Aerobic exercise evidence base, and the one that any serious anti-aging argument must adjudicate, sits at the boundary between mechanistic plausibility and human functional outcomes. On the human functional side, however, the same exercise exposure produces mixed or null effects: Hinchman 2022 (mixed), Weber 2024 (mixed), and Angevaren 2008 (unclear) collectively suggest that the cognitive and behavioral translation of those biomarker improvements is neither universal nor large. The likely mechanistic explanation is that mitochondrial biogenesis and inflammatory tone are necessary but not sufficient for cognitive or functional gain; the brain and the muscle, the actual target organs of the anti-aging claim, depend on additional mediators (cerebral blood flow, neurotrophin delivery, neuromuscular coordination, learning-dependent plasticity) that are not directly captured by the biomarkers most often measured. The boundary condition, in other words, is that biomarker improvement is best treated as a permissive substrate, not as evidence of functional benefit. The way to resolve this tension empirically is to design trials that measure both mediators and hard functional endpoints in the same cohort, with adequate power, and to register the functional endpoint as the primary outcome rather than a secondary descriptor; the existing corpus largely inverts that hierarchy, and the cross-domain disagreement is in part an artifact of that inversion.

A second load-bearing tension separates surrogate cardiometabolic endpoints from hard cardiometabolic outcomes, and the corpus is unusually candid about it. The tension is therefore not that aerobic exercise 'fails' on cardiometabolic risk — the Huang 2025 and Elsayed 2023 surrogate signals are real — but that the direction of effect is highly sensitive to what is layered on top of the exercise stimulus and to which surrogate is read. The boundary condition appears to be modality-specific: aerobic training alone produces robust fat-percentage and CRF effects, while add-ons (heat, phototherapy, pharmacotherapy) produce either redundant or partially offsetting effects on downstream hard markers. Resolution would require a head-to-head comparison of aerobic-only versus aerobic-plus-add-on designs with hard endpoints (incident diabetes, MACE, mortality) rather than continuous risk factors, and the corpus as it stands is not designed to deliver that answer; this is a textbook surrogate-versus-hard-outcome hazard and the cross-domain disagreement is essentially that hazard made visible.

Another tension is internal to the muscle function outcome class itself, and it directly threatens the strongest pro-aerobic signal in the corpus. Lo 2021, in middle-aged and older adults with multimorbidity, reports a positive effect of individualized aerobic training on physical activity and health-related physical fitness (significant at P = 0.011, P = 0.007, P = 0.019, P = 0.027, P = 0.043, P = 0.001 on the family of physical-fitness outcomes). Li 2025, in incarcerated men with DSM-IV drug dependence, reports that exercise reduces drug cravings and that cardiorespiratory fitness and inhibitory control mediate that effect (P < 0.05 to P < 0.01 on the mediation pathways). Baker 2010, in glucose-intolerant older adults, reports improved executive function (MANCOVA P = 0.04), cardiorespiratory fitness (MANOVA P = 0.03), and insulin sensitivity (P = 0.05) after six months of aerobic exercise. Against that, Dhahbi 2025 (review) reports a null direction, Hinchman 2022 reports a mixed direction, Weber 2024 reports a mixed direction, and Angevaren 2008 reports an unclear direction. The reason these otherwise comparable aerobic interventions disagree at the muscle function level is most plausibly a population × dose × engagement interaction: the positive trials enroll participants whose baseline aerobic capacity or clinical risk profile leaves substantial headroom for adaptation (multimorbid older adults, glucose-intolerant older adults, sedentary substance-dependent men), whereas the mixed and null reviews aggregate studies that include already-active or already-high-functioning comparators. The boundary condition is therefore that aerobic training reliably improves muscle function in sedentary, clinically vulnerable, or deconditioned adults, but produces smaller or undetectable effects in already-active adults, and reviews that pool across these populations dilute the signal. Resolution would require stratified meta-analysis with baseline fitness as a moderator, and a transparent reporting of adherence-adjusted effect sizes, neither of which is consistently available in the corpus.

Another tension runs between cognitive and brain-structural endpoints, where the corpus is striking for the way it separates biomarker plausibility from clinical translation. The mechanistic candidate for the disagreement is that hippocampal volume change and functional connectivity change are slow, time-dependent, and engagement-dependent, while the cognitive batteries used in many trials are noisy, ceiling-affected in healthy adults, and insensitive over the short follow-up windows that dominate the corpus. The boundary condition is that brain-network and brain-volume benefits accrue with at least 6–12 months of sustained aerobic engagement and are most detectable in participants with measurable baseline impairment, whereas shorter trials in cognitively healthy adults tend to underestimate the effect. Resolution would require pre-registered, duration-graded, baseline-stratified cognitive RCTs, and the corpus does not yet provide that body of evidence. Until it does, the cognitive claim for aerobic exercise should be reported as 'mechanistically supported, clinically suggestive, not yet definitive,' which is the most that the present cross-study disagreement map will support.

A fifth and final tension cuts across the dosing/pharmacokinetics class and is, in some ways, the most uncomfortable for the anti-aging framing. The mechanistic candidate for the disagreement is that neurotrophin delivery to the brain is gated by both the magnitude of the peripheral CRF response and by central mechanisms (sleep, mood, vascular integrity) that aerobic exercise alone does not fully control, and that a drug-on-exercise interaction can either potentiate or saturate the shared downstream pathway. The boundary condition is that aerobic exercise's effect on neurotrophic and pharmacodynamic intermediates is not linear in dose, is not uniform across clinical populations, and is highly sensitive to what is co-administered. Resolution would require factorial designs that cross exercise dose with candidate pharmacologic adjuncts, with neurotrophin and hard cognitive endpoints measured on the same schedule. The cross-domain reading of the corpus, taken as a whole, is therefore that aerobic exercise is best characterized as a context-dependent, population-conditional, dose-graded intervention whose strongest claims are mechanistic and whose functional and hard-outcome claims remain in tension with each other in a way the current evidence base is not yet equipped to fully resolve.

Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 31 curated reference papers, the evidence base for Aerobic exercise shows a context-dependent profile. Positive signals appear in: muscle function, contextual other. Negative signals appear in: cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Aerobic exercise anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

Threat 1: The cardiometabolic spine of the aerobic-exercise case is fractured by a direct, severe head-to-head disagreement. The two trials differ on population baseline risk (sedentary middle-aged versus obese seniors), co-intervention (heat versus phototherapy), and outcome panel (vascular versus haemostatic), so the apparent contradiction may mask two genuine sub-effects. If the disagreement is real and not an artefact of design heterogeneity, then the thesis that aerobic exercise reliably improves cardiometabolic surrogates is too strong and warrants qualification by baseline risk and adjunct modality.

Threat 2: The muscle-function and cognition cluster — the strongest convergent signal across the corpus — is itself contested at severity 4 in the cross-study disagreement map. Baker 2010 found that six months of aerobic exercise improved executive function (MANCOVA P = 0.04), cardiorespiratory fitness (MANOVA P = 0.03), and insulin sensitivity (P = 0.05) in older adults with glucose intolerance, and Lo 2021 reported consistent gains across physical activity and health-related fitness in middle-aged and older multimorbid adults (P = 0.011, P = 0.007, P = 0.019). Against this, Hinchman 2022 reported a mixed pattern in sedentary aging adults at risk of cognitive decline, with significant within-group effects (P = 0.01, P < 0.001) but engagement-driven rather than dose-driven cognitive benefit, and Weber 2024 concluded a mixed effect across female cognition studies (P < 0.01 to P = 0.048). We interpret the most parsimonious reading as: aerobic exercise probably improves the upstream mediators (fitness, insulin sensitivity, executive function) more reliably than the downstream cognitive endpoints, and the conversion from mediator to clinical benefit remains context-dependent and warrants longer follow-up with adjudicated cognitive endpoints.

Evidence Summary

The evidence base for this synthesis comprises 31 included sources. The evidence-tier distribution is: B2 (n=27), B1 (n=4). By directness, the breakdown is: indirect (n=20), review (n=11). 24 of 31 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: adults; older adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Resolution criteria: This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The corpus is dominated by short-duration exercise physiology studies, mechanistic and indirect entries, and reviews of intermediate outcomes, with a striking absence of long-term randomized trials evaluating hard clinical endpoints such as all-cause mortality, incident frailty, or hip fracture in non-diabetic community-dwelling adults. The result is that headline inferences about "anti-aging" benefit rest on surrogate markers rather than on hard endpoints, a pattern consistent with the surrogate endpoint cautions articulated by Ioannidis 2005.

Several clinically salient outcomes are supported by only a single source in the corpus, so any synthesis-level claim about them cannot be replicated within the available evidence. With only one human RCT per outcome in these pockets, the synthesis cannot test whether each isolated effect reproduces across populations, modalities, or laboratories, and single-study generalizations therefore carry elevated risk.

The enrolled populations are narrowly drawn, which constrains external validity. Translational relevance to humans remains uncertain. Because none of the trials enrolled frail older adults meeting EWGSOP2 sarcopenia cutoffs (27 kg grip strength for men, 16 kg for women; Cruz-Jentoft 2019) or adults with the gait-speed deficits that Studenski 2011 (0.8 m/s) and Cesari 2009 (0.6 m/s) use to define impaired mobility, the corpus cannot speak to the very populations in which anti-aging claims would matter most.

Several clinically attractive claims rest on mechanistic or short-window evidence with no corresponding human outcome trial. Likewise, the mitochondrial and DNA-copy-number evidence in Latimer 2022 is paired with a withdrawal-design observation rather than a sustained clinical endpoint. The mechanism-to-clinic gap is therefore the principal ceiling on the Aerobic exercise anti-aging synthesis as currently constituted, and it cannot be closed without long-horizon human RCTs in the populations for whom the external-validacy boundary currently ends.

Conclusion

The strongest counterweight to any enthusiastic reading of this literature is the cross-study disagreements catalogued in the Cross-Domain Synthesis, and in particular the severity-4 and severity-5 disagreements on muscle function and cardiometabolic outcomes — for example, Baker 2010 (positive) versus Hinchman 2022 (mixed) and Weber 2024 (mixed), and Steward 2025 (negative) versus Elsayed 2023 (positive) on cardiometabolic endpoints — which suggest that the apparent effect of Aerobic exercise is highly sensitive to population, comparator, dose and duration in ways that no single trial has yet resolved. A second unresolved issue is mechanistic-clinical translation: mechanistic plausibility. Practically, the recommended next step is a registered, adequately powered, longer-duration RCT in older adults that uses harmonised endpoints, an active comparator, and pre-specified stratification by baseline function, while clinicians should be cautious about marketing Aerobic exercise as a standalone anti-aging intervention. Pending further trials establishing hard-outcome benefit, the current evidence appears to support Aerobic exercise as a component of general-health maintenance rather than as a proven geroprotective therapy; that distinction between general-health support and a validated anti-aging claim should be made explicit in any patient-facing communication, in keeping with the conservative reading demanded by the Ioannidis 2005 surrogate-endpoint caution.

A defensible next study should pre-specify which endpoint layer it intends to test, align intervention exposure with that endpoint, and report functional or safety tradeoffs with the same visibility as benefit signals. Agreement across mechanistic, intermediate, functional, and hard-clinical layers would support stronger inference than any isolated signal; disagreement across those layers should be treated as a design problem rather than averaged into a single geroprotective claim.

What This Synthesis Adds

This synthesis maps 31 included sources on Aerobic exercise across 6 outcome classes and 148 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

The strongest unresolved contrast is the disagreement between Steward 2025 and Elsayed 2023 on cardiometabolic (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Weber 2024, Zheng 2019, Baker 2010, Angevaren 2008) emphasize convergent signals on Aerobic exercise. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cardiometabolic	0	4	negative, null, positive	conflict-resolution gap
muscle function	0	7	mixed, null, positive, unclear	conflict-resolution gap
immune	0	1	mixed	direct interventional hard-endpoint gap
contextual adjacent evidence	0	17	null, positive, unclear	direct interventional hard-endpoint gap
dosing and pharmacokinetics	0	1	null	direct interventional hard-endpoint gap
skeletal, fracture, and bone	0	1	null	direct interventional hard-endpoint gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cardiometabolic: conflict-resolution gap	0 direct and 4 indirect sources; direction profile: negative, null, positive
P2	muscle function: conflict-resolution gap	0 direct and 7 indirect sources; direction profile: mixed, null, positive, unclear
P3	immune: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: mixed
P4	contextual adjacent evidence: direct interventional hard-endpoint gap	0 direct and 17 indirect sources; direction profile: null, positive, unclear
P5	dosing and pharmacokinetics: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: null

Next-Study Design Recommendation

The next high-yield study for Aerobic exercise should target the cardiometabolic evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Weber 2024; tier=B1; directness=review; endpoint=muscle function; direction=mixed; representative statistic=P < 0.001.
• Zheng 2019; tier=B1; directness=review; endpoint=immune; direction=mixed; representative statistic=P = 0.0002.
• Baker 2010; tier=B1; directness=review; endpoint=muscle function; direction=positive; representative statistic=P = 0.03.
• Angevaren 2008; tier=B1; directness=review; endpoint=muscle function; direction=unclear.
• Tsuji 2023; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.003.
• Steward 2025; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=negative; representative statistic=P = 0.029.
• Elsayed 2023; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.001.
• Jayedi 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P = 0.004.
• Latimer 2022; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001.
• OConnor 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.005.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Role of Cardiorespiratory Fitness, Aerobic, Exercise and Sports Participation in Female Cognition: A Scoping Review: outcome=muscle function; directness=review; tier=B1; direction=mixed; claims=19.
• Effect of Aerobic Exercise on Inflammatory Markers in Healthy Middle-Aged and Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials: outcome=immune; directness=review; tier=B1; direction=mixed; claims=18.
• Aerobic Exercise Improves Cognition for Older Adults with Glucose Intolerance, A Risk Factor for Alzheimer's Disease: outcome=muscle function; directness=review; tier=B1; direction=positive; claims=3.
• Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment: outcome=muscle function; directness=review; tier=B1; direction=unclear; claims=1.
• Home-based high-intensity interval training improves cardiorespiratory fitness: a systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=146.
• Post‐exercise hot water immersion enhances haemodynamic and vascular benefits of exercise without further improving cardiorespiratory fitness, glucose, lipids or inflammation: outcome=cardiometabolic; directness=indirect; tier=B2; direction=negative; claims=138.
• Effect of exercise training with laser phototherapy on homeostasis balance resistant to hypercoagulability in seniors with obesity: a randomized trial: outcome=cardiometabolic; directness=indirect; tier=B2; direction=positive; claims=118.
• Aerobic Exercise and Weight Loss in Adults: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=112.
• Whole-body and muscle responses to aerobic exercise training and withdrawal in ageing and COPD: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=90.
• Effects of pioglitazone with and without exercise training on cardiorespiratory fitness and oxygen uptake kinetics in type 2 diabetes: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=80.
• Effects of exercise on body fat percentage and cardiorespiratory fitness in sedentary adults: a systematic review and network meta-analysis: outcome=cardiometabolic; directness=review; tier=B2; direction=null; claims=73.
• Effects of Upper Body Exercise Training on Aerobic Fitness and Performance in Healthy People: A Systematic Review: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=73.
• Time Course Analysis Reveals Gene-Specific Transcript and Protein Kinetics of Adaptation to Short-Term Aerobic Exercise Training in Human Skeletal Muscle: outcome=skeletal fracture bone; directness=indirect; tier=B2; direction=null; claims=67.
• Graded Versus Constant-Load Aerobic Exercise in Pediatric Leukemia Survivors: A 12-Week RCT on Cardiorespiratory Fitness and Functional Performance: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=55.
• Effects of Individualized Aerobic Exercise Training on Physical Activity and Health-Related Physical Fitness among Middle-Aged and Older Adults with Multimorbidity: A Randomized Controlled Trial: outcome=muscle function; directness=review; tier=B2; direction=positive; claims=53.
• Exercise engagement drives changes in cognition and cardiorespiratory fitness after 8 weeks of aerobic training in sedentary aging adults at risk of cognitive decline: outcome=muscle function; directness=indirect; tier=B2; direction=mixed; claims=44.
• Effectiveness of hospital-based low intensity and inspected aerobic training on functionality and cardiorespiratory fitness in unconditioned stroke patients: Importance of submaximal aerobic fitness markers: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=40.
• Aerobic physical activity to improve memory and executive function in sedentary adults without cognitive impairment: A systematic review and meta-analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=37.
• Intermittent, moderate-intensity aerobic exercise for only eight weeks reduces arterial stiffness: evaluation by measurement of stiffness parameter and pressure–strain elastic modulus by use of ultrasonic echo tracking: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=37.
• Get Moving! Increases in Physical Activity Are Associated With Increasing Functional Connectivity Trajectories in Typically Aging Adults: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=31.
• Aerobic Exercise versus Electronic Cigarette in Vascular Aging Process: First Histological Insight: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=29.
• Plasticity of Brain Networks in a Randomized Intervention Trial of Exercise Training in Older Adults: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=29.
• Impact of exercise on drug cravings: mediating role of cardiorespiratory fitness and inhibitory control: outcome=muscle function; directness=indirect; tier=B2; direction=positive; claims=23.
• Aerobic exercise for Alzheimer's disease: A randomized controlled pilot trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=18.
• Aerobic Exercise, Training Dose, and Cardiorespiratory Fitness: Effects and Relationships with Resting Plasma Neurotrophic Factors in Alzheimer’s Dementia: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=13.
• Absolute and relative reliability of acute effects of aerobic exercise on executive function in seniors: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=9.
• Promoting exercise behavior and cardiorespiratory fitness among college students based on the motivation theory: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=8.
• Prefrontal high definition cathodal tDCS modulates executive functions only when coupled with moderate aerobic exercise in healthy persons: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=8.
• World Health Organization 2020 guidelines on physical activity and sedentary behaviour: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=6.
• Physical activity and neuroplasticity in neurodegenerative disorders: a comprehensive review of exercise interventions, cognitive training, and AI applications: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=6.
• Physical Activity to Counter Age-Related Cognitive Decline: Benefits of Aerobic, Resistance, and Combined Training—A Narrative Review: outcome=muscle function; directness=review; tier=B2; direction=null; claims=3.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 5 disagreement: Steward 2025 vs Elsayed 2023; Steward 2025 (negative) vs Elsayed 2023 (positive) on cardiometabolic
• Severity 4 disagreement: Angevaren 2008 vs Weber 2024; Angevaren 2008 (unclear) vs Weber 2024 (mixed) on muscle function
• Severity 4 disagreement: Angevaren 2008 vs Hinchman 2022; Angevaren 2008 (unclear) vs Hinchman 2022 (mixed) on muscle function
• Severity 4 disagreement: Baker 2010 vs Weber 2024; Baker 2010 (positive) vs Weber 2024 (mixed) on muscle function
• Severity 4 disagreement: Baker 2010 vs Hinchman 2022; Baker 2010 (positive) vs Hinchman 2022 (mixed) on muscle function
• Severity 4 disagreement: Weber 2024 vs Li 2025; Weber 2024 (mixed) vs Li 2025 (positive) on muscle function
• Severity 4 disagreement: Weber 2024 vs Dhahbi 2025; Weber 2024 (mixed) vs Dhahbi 2025 (null) on muscle function
• Severity 4 disagreement: Weber 2024 vs Lo 2021; Weber 2024 (mixed) vs Lo 2021 (positive) on muscle function

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Marterer 2023, Horvath 2022, Hoffmann 2021, Dorsman 2020, Damay 2023, Voss 2010, Morris 2017, Thomas 2021, Li 2022, Ezzdine 2025, Bull 2020, Perera 2006.

References

• Tsuji 2023. Home-based high-intensity interval training improves cardiorespiratory fitness: a systematic review and meta-analysis. BMC Sports Science, Medicine and Rehabilitation, 2023. DOI: 10.1186/s13102-023-00777-2. PMID: 38053128.
• Steward 2025. Post‐exercise hot water immersion enhances haemodynamic and vascular benefits of exercise without further improving cardiorespiratory fitness, glucose, lipids or inflammation. The Journal of Physiology, 2025. DOI: 10.1113/JP288873. PMID: 40719540.
• Elsayed 2023. Effect of exercise training with laser phototherapy on homeostasis balance resistant to hypercoagulability in seniors with obesity: a randomized trial. Scientific Reports, 2023. DOI: 10.1038/s41598-023-30550-x. PMID: 36869148.
• Jayedi 2024. Aerobic Exercise and Weight Loss in Adults. JAMA Network Open, 2024. DOI: 10.1001/jamanetworkopen.2024.52185. PMID: 39724371.
• Latimer 2022. Whole-body and muscle responses to aerobic exercise training and withdrawal in ageing and COPD. The European Respiratory Journal, 2022. DOI: 10.1183/13993003.01507-2021. PMID: 34588196.
• OConnor 2025. Effects of pioglitazone with and without exercise training on cardiorespiratory fitness and oxygen uptake kinetics in type 2 diabetes. Diabetes, Obesity & Metabolism, 2025. DOI: 10.1111/dom.16648. PMID: 40735972.
• Marterer 2023. Effects of Upper Body Exercise Training on Aerobic Fitness and Performance in Healthy People: A Systematic Review. Biology, 2023. DOI: 10.3390/biology12030355. PMID: 36979047.
• Huang 2025. Effects of exercise on body fat percentage and cardiorespiratory fitness in sedentary adults: a systematic review and network meta-analysis. Frontiers in Public Health, 2025. DOI: 10.3389/fpubh.2025.1624562. PMID: 40746688.
• Egan 2013. Time Course Analysis Reveals Gene-Specific Transcript and Protein Kinetics of Adaptation to Short-Term Aerobic Exercise Training in Human Skeletal Muscle. PLoS ONE, 2013. DOI: 10.1371/journal.pone.0074098. PMID: 24069271.
• Elnaggar 2026. Graded Versus Constant-Load Aerobic Exercise in Pediatric Leukemia Survivors: A 12-Week RCT on Cardiorespiratory Fitness and Functional Performance. Healthcare, 2026. DOI: 10.3390/healthcare14050608.
• Lo 2021. Effects of Individualized Aerobic Exercise Training on Physical Activity and Health-Related Physical Fitness among Middle-Aged and Older Adults with Multimorbidity: A Randomized Controlled Trial. International Journal of Environmental Research and Public Health, 2021. DOI: 10.3390/ijerph18010101. PMID: 33375668.
• Hinchman 2022. Exercise engagement drives changes in cognition and cardiorespiratory fitness after 8 weeks of aerobic training in sedentary aging adults at risk of cognitive decline. Frontiers in Rehabilitation Sciences, 2022. DOI: 10.3389/fresc.2022.923141. PMID: 36189006.
• Horvath 2022. Effectiveness of hospital-based low intensity and inspected aerobic training on functionality and cardiorespiratory fitness in unconditioned stroke patients: Importance of submaximal aerobic fitness markers. Medicine, 2022. DOI: 10.1097/MD.0000000000031035. PMID: 36281113.
• Tanaka 2012. Intermittent, moderate-intensity aerobic exercise for only eight weeks reduces arterial stiffness: evaluation by measurement of stiffness parameter and pressure–strain elastic modulus by use of ultrasonic echo tracking. Journal of Medical Ultrasonics (2001), 2012. DOI: 10.1007/s10396-012-0408-1. PMID: 23565047.
• Hoffmann 2021. Aerobic physical activity to improve memory and executive function in sedentary adults without cognitive impairment: A systematic review and meta-analysis. Preventive Medicine Reports, 2021. DOI: 10.1016/j.pmedr.2021.101496. PMID: 34377632.
• Dorsman 2020. Get Moving! Increases in Physical Activity Are Associated With Increasing Functional Connectivity Trajectories in Typically Aging Adults. Frontiers in Aging Neuroscience, 2020. DOI: 10.3389/fnagi.2020.00104. PMID: 32410981.
• Damay 2023. Aerobic Exercise versus Electronic Cigarette in Vascular Aging Process: First Histological Insight. International Journal of Vascular Medicine, 2023. DOI: 10.1155/2023/8874599. PMID: 37533734.
• Voss 2010. Plasticity of Brain Networks in a Randomized Intervention Trial of Exercise Training in Older Adults. Frontiers in Aging Neuroscience, 2010. DOI: 10.3389/fnagi.2010.00032. PMID: 20890449.
• Li 2025. Impact of exercise on drug cravings: mediating role of cardiorespiratory fitness and inhibitory control. Frontiers in Psychology, 2025. DOI: 10.3389/fpsyg.2025.1540648. PMID: 40271371.
• Weber 2024. Role of Cardiorespiratory Fitness, Aerobic, Exercise and Sports Participation in Female Cognition: A Scoping Review. Sports Medicine - Open, 2024. DOI: 10.1186/s40798-024-00776-8. PMID: 39333320.
• Morris 2017. Aerobic exercise for Alzheimer's disease: A randomized controlled pilot trial. PLoS ONE, 2017. DOI: 10.1371/journal.pone.0170547. PMID: 28187125.
• Zheng 2019. Effect of Aerobic Exercise on Inflammatory Markers in Healthy Middle-Aged and Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Aging Neuroscience, 2019. DOI: 10.3389/fnagi.2019.00098. PMID: 31080412.
• Salisbury 2023. Aerobic Exercise, Training Dose, and Cardiorespiratory Fitness: Effects and Relationships with Resting Plasma Neurotrophic Factors in Alzheimer’s Dementia. Journal of vascular diseases, 2023. DOI: 10.3390/jvd2030027. PMID: 39328309.
• Donath 2017. Absolute and relative reliability of acute effects of aerobic exercise on executive function in seniors. BMC Geriatrics, 2017. DOI: 10.1186/s12877-017-0634-x. PMID: 29070027.
• Thomas 2021. Prefrontal high definition cathodal tDCS modulates executive functions only when coupled with moderate aerobic exercise in healthy persons. Scientific Reports, 2021. DOI: 10.1038/s41598-021-87914-4. PMID: 33875729.
• Li 2022. Promoting exercise behavior and cardiorespiratory fitness among college students based on the motivation theory. BMC Public Health, 2022. DOI: 10.1186/s12889-022-13159-z. PMID: 35418043.
• Ezzdine 2025. Physical activity and neuroplasticity in neurodegenerative disorders: a comprehensive review of exercise interventions, cognitive training, and AI applications. Frontiers in Neuroscience, 2025. DOI: 10.3389/fnins.2025.1502417. PMID: 40092068.
• Bull 2020. World Health Organization 2020 guidelines on physical activity and sedentary behaviour. British Journal of Sports Medicine, 2020. DOI: 10.1136/bjsports-2020-102955. PMID: 33239350.
• Baker 2010. Aerobic Exercise Improves Cognition for Older Adults with Glucose Intolerance, A Risk Factor for Alzheimer's Disease. J Alzheimers Dis, 2010. DOI: 10.3233/jad-2010-100768. PMID: 20847403.
• Dhahbi 2025. Physical Activity to Counter Age-Related Cognitive Decline: Benefits of Aerobic, Resistance, and Combined Training—A Narrative Review. Sports Medicine - Open, 2025. DOI: 10.1186/s40798-025-00857-2. PMID: 40381170.
• Angevaren 2008. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev, 2008. DOI: 10.1002/14651858.cd005381.pub3. PMID: 18646126.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Cesari 2009. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779. DOI: 10.1093/gerona/glp012. PMID: 19349594.
• Perera 2006. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749. DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Schulz 2010. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332. DOI: 10.1136/bmj.c332.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.